지속성 외래 복막투석 환자에서 발생한 만성 결절성 통풍 치료 1예
Febuxostat for the Treatment of Chronic Tophaceous Gout in a Patient on Continuous Ambulatory Peritoneal Dialysis
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Febuxostat은 비퓨린계 선택적 XO 억제제로 신기능 저하환자에서도 용량을 조절할 필요가 없고 특별한 부작용이 없이 요산강하 효과가 좋다. 저자들은 복막투석 환자에서 생긴만성 결절성 통풍 치료에 febuxostat을 투여하여 tophi 재발없이 혈청요산농도를 목표치로 낮게 유지할 수 있었던 증례를 경험하였기에 문헌고찰과 함께 보고하는 바이다.
Abstract
Hyperuricemic patients with gouty arthritis or tophi, a serum uric acid concentration of 8.0 mg/dL or higher, and complications should be treated with urate-lowering drugs. Conventionally, allopurinol is used to treat hyperuricemia and gout, but it is necessary to adjust the dosage according to the degree of renal impairment. Uncommonly, allopurinol may have severe or fatal side effects. The non-purine xanthine oxidase inhibitor febuxostat undergoes hepatic metabolism and may require less dose adjustment in association with renal function. It is considered to be an alternative treatment for hyperuricemic patients with chronic kidney disease. Our experience suggests that low-dose febuxostat is a promising alternative to allopurinol for the treatment of gouty arthritis or tophi in peritoneal dialysis patients.
참고문헌 (10)
- Becker MA, "The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial", Arthritis Res Ther, 12, pp.63~ (2010)
- Akimoto T, "Febuxostat for hyperuricemia in patients with advanced chronic kidney disease", Drug Target Insights, 8, pp.39~43 (2014)
- Iseki K, "Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort", Am J Kidney Dis, 44, pp.642~650 (2004)
- Becker MA, "Febuxostat compared with allopurinol in patients with hyperuricemia and gout", N Engl J Med, 353, pp.2450~2461 (2005)
- Hosoya T, "The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study", Trials, 15, pp.26~ (2014)
- 정영옥, "통풍의 합병증 치료", 대한내과학회지, 80(3), pp.269~272 (2011), 대한내과학회
- Love BL, "Urate-lowering therapy for gout: focus on febuxostat", Pharmacotherapy, 30, pp.594~608 (2010)
- Horikoshi R, "Febuxostat for hyperuricemia: experience with patients on chronic hemodialysis treatment", Clin Exp Nephrol, 17, pp.149~150 (2013)
- 박원, "통풍의 치료", 대한내과학회지, 80(3), pp.260~268 (2011), 대한내과학회
- Tojimbara T, "Efficacy and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in kidney transplant recipients", Transplant Proc, 46, pp.511~513 (2014)